Related Experiment Video
Updated: Jul 12, 2026

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
Colorectal cancer landscape from gut microbiota: Insights into mutations, epigenetic dysregulation, and immune
Yunze Li1, Ying Yang2, Xixia Zhang3
1Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, PR China.
Abstract:
This review explores how gut microbiota reshapes colorectal cancer (CRC) molecular landscape, driving initiation/progression via key mechanisms. Microbes/metabolites cause driver mutations (DNA damage, signaling interference) and alter epigenetics (DNA methylation, histone modifications, ncRNAs) to boost tumor cell proliferation/survival. Dysbiosis disrupts tumor immune microenvironment (TIME) by impairing immune cells and increasing immunosuppressive factors, fostering immune evasion.Integrating molecular biology, microbiology, and immunology, we show microbial changes are causal in oncogenesis, with species acting distinctly across tumor stages. These insights clarify CRC pathogenesis and support microbiota-based prevention, diagnosis, treatment. Targeting microbes/metabolites or signaling pathways could cut CRC risk, improve early detection, and boost therapy. The review highlights microbiota-targeted therapy's promise and guides future research/clinical translation.
Related Concept Videos
Inflammatory Bowel Disease III: Crohn's Disease
Microbiota Modulation by Antibiotics
Dysbiosis of the Gut Microbiota
Microbiota of the Large Intestine
The Tumor Microenvironment
The Tumor Microenvironment
